Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

$455.8M

Market Cap • 5/8/2025

2011

(14 years)

Founded

2019

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Fremont

Headquarters • California